How to Design Protocols for Direct-to-Patient (DTP) Drug Delivery in Clinical Trials

Direct-to-Patient (DTP) drug delivery is a cornerstone of decentralized clinical trials (DCTs), offering improved access, patient retention, and operational continuity. This model involves shipping investigational medicinal products (IMPs) directly to participants’ homes under controlled, compliant conditions. Designing protocols that incorporate DTP delivery requires careful planning, regulatory awareness, and stakeholder coordination. This tutorial provides a comprehensive guide to building DTP into your protocol design effectively.

Why Use Direct-to-Patient (DTP) Delivery in Trials?

As clinical trials move away from site-centric designs, the need for reliable, compliant home delivery systems has grown. DTP models enable:

• Participation from patients in remote or underserved regions
• Improved adherence through convenience and reduced burden
• Continuation of trials during public health crises
• Better alignment with Pharma GMP principles in supply chain management

Leading sponsors have embraced DTP delivery for its patient-centric benefits and ability to reduce site dependency.

Key Protocol Design Considerations for DTP:

When integrating DTP into a clinical trial protocol, sponsors must address the following:

1. Eligibility Criteria: Define which patients can receive DTP shipments (e.g., stable, capable of self-administration).
2. Logistics Workflow: Outline delivery timelines, storage instructions, and contingency plans.
3. Drug Accountability: Detail how receipt, usage, and returns will be tracked.
4. Safety Monitoring: Ensure participants are adequately supported for AE/SAE reporting remotely.
5. Training: Include procedures for educating patients and caregivers on IMP handling and dosing.

Steps to Develop a DTP-Enabled Protocol:

1. Define the DTP Delivery Process in the Protocol:

Clearly describe the flow of drug shipment, from the sponsor or central pharmacy to the patient’s residence:

• Who authorizes shipment (e.g., site, sponsor, IRT system)
• Which courier is responsible and how shipment tracking is managed
• Expected timelines and communication between stakeholders

2. Incorporate Regulatory and Ethical Safeguards:

As per EMA and CDSCO expectations, ensure:

• DTP delivery is approved by the ethics committee
• Participant informed consent includes DTP details
• Temperature and chain-of-custody documentation is maintained

3. Develop or Update SOPs for DTP Execution:

SOPs must be in place for:

• IMP dispatch and receipt logging
• Participant training and support
• Returns management and destruction protocols
• Deviation handling and adverse event escalation

These SOPs can be adapted from Pharma SOP templates used in other decentralized activities.

Defining Roles and Responsibilities:

Ensure clarity among stakeholders regarding who does what:

• Pharmacist: Prepares and dispatches study medication
• Courier: Ensures secure delivery with temperature control
• Participant: Confirms receipt and adheres to dosing
• Site staff: Provides remote support and monitors adherence

Accountability records must be complete and stored in the trial master file (TMF).

Technology Tools to Support DTP:

Technology is vital to ensure control and documentation:

• IRT (Interactive Response Technology) for shipment control
• eConsent systems reflecting DTP details
• eDiary and ePRO tools for adherence and AE reporting
• Temperature loggers and GPS-tracked courier systems

These systems must be validation-compliant and audit-ready.

Risk Management Strategies for DTP Protocols:

• Missed deliveries: Include protocol-defined visit windows and reshipment procedures
• Temperature excursions: Define acceptance/rejection criteria and documentation needs
• Incorrect dosing: Provide visual guides and live support for patients
• Lost medication: Incorporate tracking numbers and delivery confirmations

Conduct risk assessments and mitigation planning during protocol development.

Regulatory and GCP Compliance in DTP Models:

Regulatory authorities accept DTP delivery when:

• Drug stability and labeling are suitable for patient use
• Proper documentation and reconciliation systems are in place
• Patient safety is continuously monitored

Reference frameworks such as Stability testing protocols ensure product integrity during transit.

Patient Communication and Support:

Design your protocol to include:

• Welcome packets with clear dosing instructions
• 24/7 support lines for clinical questions
• Reminders and adherence tools
• Training assessments and comprehension checks

These activities support pharmaceutical compliance and patient retention alike.

Measuring DTP Effectiveness During the Trial:

Track key metrics such as:

• On-time delivery rates
• Return rates and accountability completeness
• Adherence to dosing
• Participant-reported satisfaction and usability

These metrics support continuous improvement and trial scalability.

Conclusion:

Designing protocols that support Direct-to-Patient drug delivery allows sponsors to reach more participants, enhance trial flexibility, and reduce site burdens. However, it requires detailed planning, robust SOPs, and technological infrastructure to ensure compliance and patient safety. By following structured steps and learning from regulatory guidance and prior experience, clinical trial teams can confidently adopt DTP delivery within their decentralized study models.